Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.
about
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerThe presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast canceThe Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer.The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma.Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patientsTumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer.Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.Autophagy inhibition upregulates CD4+ tumor infiltrating lymphocyte expression via miR-155 regulation and TRAIL activationImmunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.CD8+ and FoxP3+ T-cell infiltration in actinic cheilitis.Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets.Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer.Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy.The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).In rectal cancer, the type of desmoplastic response after preoperative chemoradiotherapy is associated with prognosis.Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer
P2860
Q26798074-64FF3E78-10CF-473E-A325-4F3A02D73F1EQ36862687-17381170-A37A-4F51-9A47-5810DF94ACD4Q36895458-27F27DEB-9497-4C61-A5A9-1E2B63954A91Q37423348-AE34548D-316E-4BA3-8DD5-E64DB5C86928Q37530339-9034A120-D5CC-405D-B1B1-91E475F78374Q37536862-535A280E-68C5-43AE-8C68-AF39577E848FQ37544396-2C858378-8DA8-43A0-B25F-5BD684BA7CB5Q38734804-A9308F3C-45F7-45A4-9B2A-7B0ED4501CF4Q38771946-A240DD37-5C57-4B2C-984E-8BAEBD8EBB7BQ40214905-FDD4397A-C257-4BB7-A7A7-4EE44666CE6CQ40404266-ED43B7F4-98A0-40D9-A622-B28242F6A44DQ41701909-B3F6FBF4-E816-4B61-8010-8488A02803C5Q41914210-904EDFCD-50CF-4CD8-91CA-42DE4E268F36Q42503675-8A17788E-4B11-41E2-83F2-135D1182153FQ47564468-2CB524DF-48A9-4259-90C1-B4CE3CB6F33CQ47653400-425699A2-C150-4143-81E5-6FBBC97D4F87Q47863345-2D3F95D0-3842-45F7-A79B-55A649C06727Q50246934-E24CD845-7A11-4D74-82EB-7E6F9827EDA0Q50941364-C290AB1E-BD82-490E-8999-F23386351606Q52626663-930E1CF5-C4DA-4902-B3FC-92D319D57881Q52771838-715E4291-2F77-428D-AA54-B6509015E008Q53565862-571F8B12-9F9A-4B52-8782-114BE7A42C7EQ58750668-E2C47658-8E2F-475B-BCE9-6FC72CCB5888
P2860
Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tumor-infiltrating CD8+ and FO ...... e to neoadjuvant chemotherapy.
@ast
Tumor-infiltrating CD8+ and FO ...... e to neoadjuvant chemotherapy.
@en
Tumor-infiltrating CD8+ and FO ...... e to neoadjuvant chemotherapy.
@nl
type
label
Tumor-infiltrating CD8+ and FO ...... e to neoadjuvant chemotherapy.
@ast
Tumor-infiltrating CD8+ and FO ...... e to neoadjuvant chemotherapy.
@en
Tumor-infiltrating CD8+ and FO ...... e to neoadjuvant chemotherapy.
@nl
prefLabel
Tumor-infiltrating CD8+ and FO ...... e to neoadjuvant chemotherapy.
@ast
Tumor-infiltrating CD8+ and FO ...... e to neoadjuvant chemotherapy.
@en
Tumor-infiltrating CD8+ and FO ...... e to neoadjuvant chemotherapy.
@nl
P2093
P2860
P1476
Tumor-infiltrating CD8+ and FO ...... e to neoadjuvant chemotherapy.
@en
P2093
Akihiko Suzuki
Go Watanabe
Hironobu Sasano
Hisashi Hirakawa
Kentaro Tamaki
Minoru Miyashita
Monica Chan
Noriaki Ohuchi
Noriko Nemoto
Saki Nakagawa
P2860
P2888
P304
P356
10.1007/S10549-014-3197-Y
P407
P50
P577
2014-11-14T00:00:00Z
P6179
1013654783